Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering Desloratadine Launch Ads In U.K. Include Decongestant Claim

Executive Summary

Schering-Plough's launch campaign for desloratadine in the U.K. includes a claim that the antihistamine has decongestant properties.

You may also be interested in...



Schering Desloratadine Onset Of Action Is 1-2 Hours - EU Review Document

Schering-Plough's clinical data for desloratadine supports a one-to-two hour onset of action claim for the antihistamine, the European Public Assessment Report states.

Aventis Allegra Once-Daily New Prescription Market Share Reaches 13%

Aventis' once-daily Allegra (fexofenadine) represents approximately half of the antihistamine's total new prescription market share, Pharmaceuticals CEO Richard Markham said during an analyst meeting in London March 2.

Aventis Allegra Once-Daily New Prescription Market Share Reaches 13%

Aventis' once-daily Allegra (fexofenadine) represents approximately half of the antihistamine's total new prescription market share, Pharmaceuticals CEO Richard Markham said during an analyst meeting in London March 2.

Related Content

UsernamePublicRestriction

Register

PS037340

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel